Address And Details

840 Newport Center Dr., Ste. 100 , Newport Beach, CA 92660
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

The Fund seeks maximum total return, consistent with preservation of capital and prudent investment management. The Fund seeks to achieve its investment objective by investing under normal circumstances at least 80% of its assets in Fixed Income Instruments. The Fund will invest under normal circumstances in Fixed Income Instruments that are economically tied to at least three non-U.S. countries. The Fund s investments in Fixed Income Instruments may be represented by forwards or derivatives such as options, futures contracts or swap agreements. Fixed Income Instruments include bonds, debt securities and other similar instruments issued by various U.S. and non-U.S. public- or private-sector entities. The Fund will normally limit its foreign currency exposure (from non-U.S. dollar-denominated securities or currencies) to 20% of its total assets.

Net Asset Value

as of 6:01 PM ET 09/24/2021

Performance

  • 1 Week
  • -0.28%
  • 1 Month
  • -0.91%
  • 3 Months
  • 0.00%
  • 1 Yr Return
  • -1.09%
  • 5 Yr Return
  • +2.94%

Equity Sector Breakdown

ConsumerDurables n/a
Energy n/a
Finance n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Bonds 116.02%
Cash 7.26%
Preferred 1.63%
Stocks 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Other -24.91%
Total Net Assets 57.44 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -0.40 0.45 1.87
Beta 0.61 0.51 0.63
R Squared 0.38 0.28 0.15
Std Deviation 3.42 3.12 4.77
Sharpe Ratio 0.66 0.48 n/a

Purchase Information

as of 5:58 PM ET 09/23/2021
Minimum Initial $1000
Minimum Additional $50
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 05/31/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 05/31/2021
1 Year
  • +1.31%
  • +2.63%
+1.31% +2.63%
3 Year
  • +3.31%
  • +3.23%
+3.31% +3.23%
10 Year
  • +4.02%
  • +4.14%
+4.02% +4.14%
Life Of Fund
  • +4.80%
  • +4.83%
+4.80% +4.83%

Top 10 Holdings

Symbol Company Name % Of Assets
n/a

Recent Articles from TheStreet

China Power Firms Suspend Publication Of Coal Data, Frustrating Analysis Of Industrial Production

Jim Cramer's Read on Industrial Production

Latest data remains encouraging for economy.

United Airlines

United Airlines Faces Department of Transportation Fine

United Airlines faces a $1.9 million fine from the Department of Transportation for violating federal statutes and a DOT rule prohibiting long tarmac delays.

NYSE Trader Lead

Jim Cramer IDs an Underappreciated Investing Rule

It's not enough to just identify stocks you want to own.

Home Construction, and Regional and Community Bank ETFs Reflect a Healthy Housing Market

Jim Cramer Says Latest Housing Data is Mixed for Millenials

There are signs more rental units are being built, but single family dwellings are still tight.

Closing Bell: Rite Aid Spikes on FTC Negotiations; U.S. Stocks Fall

Rite Aid Teams With Uber Eats for Nationwide On-Demand Delivery

Rite Aid expands its on-demand delivery options, adding a partnership with Uber Technologies to deliver products nationwide through Uber Eats.

Amazon Prime Lead

Whole Foods Adds Service Fee for Amazon Prime Deliveries

Amazon's Whole Foods Market is ending free deliveries for Amazon Prime members, as it will add a $9.95 service fee beginning in October.

FedEx Lead

FedEx Is a Sell, Guilfoyle Says

Delivery giant recently missed estimates and has been late to raise prices.

intel (4)

Intel Starts Construction of Two Arizona Computer Chip Factories

Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.

A technician works with genome samples at a biotech lab in Beijing. Photo: Reuters

Bret Jensen: Two Biotechs to Consider

Things are looking up for these drug companies as they make progress with the FDA